Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ANT3310 Alone and with Meropenem in Healthy Subjects
NCT05905913Phase 1Completed
- Sponsor
- Antabio
- Start
- Apr 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pilabactam in hospital-acquired bacterial pneumonia (HAP), ventilator-associated pneumonia (VAP), complicated urinary tract infection (cUTI) and 1 more (6 arms), sponsored by Antabio. Primary endpoint: Treatment Emergent Adverse Events up to 11 days. Started Apr 2023; status: completed.
02
Drugs
pilabactam
03
Conditions
hospital-acquired bacterial pneumonia (HAP)ventilator-associated pneumonia (VAP)complicated urinary tract infection (cUTI)Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on NCT05905913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05905913.